Apricus Biosciences (APRI) Stock Research, Analysis & News

Quick Analysis on Apricus Biosciences (APRI) Stock as of December 12, 2017

The Stock pays no dividend
Average trading volume is relatively low at 0
(See more information about Apricus Biosciences (APRI) Stock below)

Apricus Biosciences (APRI) Stock Profile Summary

NexMed, Inc. engages in designing and developing pharmaceutical products based on its patented NexACT drug delivery technology. The NexACT drug delivery technology is designed to enhance the delivery of an active drug to improve therapeutic outcomes and reduce systemic side effects that accompany oral and injectable medications. The companys proprietary topical nail solution, NM100060, is a Phase III clinical trial product for the treatment of onychomycosis (nail fungal infection). Its products also include Vitaros, a Phase III clinical trial topical alprostadil-based cream treatment for patients with erectile dysfunction; and Femprox, a Phase II clinical trial alprostadil-based cream product for the treatment of female sexual arousal disorder. In addition, NexMed focuses on developing treatments for psoriasis, cancer inflammation, pain, and wound healing. Further, the company, through its subsidiary, Bio-Quant, Inc., operates as a specialty biotech contract research organization that provides services in the areas of non-good laboratory practices in vitro and in vivo contract drug discovery, as well as pre-clinical development services specializing in oncology, inflammation, immunology, and metabolic diseases. Bio-Quant, Inc. also conducts studies in the areas of in vitro and in vivo pharmacology, pharmacokinetics, and toxicology to support pre-investigational new drug enabling packages, as well as sells diagnostic kits. The company was founded in 1987 and is headquartered in San Diego, California.

Apricus Biosciences (APRI) Stock Key Statistics Research and Analysis as of December 12, 2017

Apricus Biosciences (APRI) Stock Competitor Research and Analysis

Pfizer Inc. (PFE)Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)Novartis AG (NVS)
AstraZeneca PLC (AZN)Abbott Laboratories (ABT)

Stock Research on Apricus Biosciences (APRI)

Latest Market News on Apricus Biosciences (APRI)


Click here to find the latest news on Apricus Biosciences (APRI)

Looking for Market Opportunties?


Today's Most Active Stocks
Today's Biggest Price % Gainers
Today's Biggest Price % Losers
Today's Unusual Rising Volume Stocks
Today's Unusual Falling Volume Stocks
Research Reports
Earning Calendar
ETF Center

See other companies in the same industry

Pfizer Inc. (PFE)
Amgen Inc. (AMGN)
Biogen Idec Inc. (BIIB)
Genzyme Corp. (GENZ)
Gilead Sciences Inc. (GILD)
Life Technologies Corporation (LIFE)
Teva Pharmaceutical Industries Limited (TEVA)
Watson Pharmaceuticals Inc. (WPI)
King Pharmaceuticals Inc. (KG)
Mylan, Inc. (MYL)
Johnson & Johnson (JNJ)
GlaxoSmithKline plc (GSK)
Sanofi-Aventis (SNY)
Novartis AG (NVS)
AstraZeneca PLC (AZN)
Abbott Laboratories (ABT)